EXPIRED
Department of Health and Human Services
Participating Organizations
Centers for Disease
Control and Prevention (CDC), (http://www.cdc.gov/)
Components of Participating Organizations
National Center for Injury Prevention and Control (NCIPC/CDC), (http://www.cdc.gov/ncipc/)
Title: Urban Partnership Academic Centers of Excellence
(U-PACE)
The CDC policies,
guidelines, terms, and conditions stated in this announcement may differ from
those used by the NIH.
Authority: This program is authorized under
sections 317(k)(2) and 391(a) of the Public Health Service Act [42 U.S.C.
Sections 247b(k)(2) and 280b(a), as amended.
Announcement Type
New
Request For Applications (RFA) Number: RFA-CE-06-008
Catalog of Federal Domestic Assistance Number
93.136, Injury
Prevention and Control Research and State and Community Based Programs
Key Dates
Release Date: February 16, 2006
Letters of
Intent Receipt Date: February 28, 2006
Application
Receipt Dates: March 30, 2006
Peer
Review Date: May 2006
Council
Review Date: June 2006
Earliest
Anticipated Start Date: September 2006
Additional
Information To Be Available Date: February 14, 2006
Technical assistance will be available for potential
applicants during one conference call. The call for eligible applicants will be
held on February 14, 2006 from 2:00 p.m. to 3:30 p.m. (Eastern Time). The conference can be accessed by calling 1-877-951-7375 and
entering access code 603639.
Expiration
Date: March 31, 2006
Due Dates for E.O. 12372
Executive Order
12372 does not apply to this program.
Additional
Overview Content
Executive Summary
Table of Contents
Part I Overview Information
Part II Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
Section II. Award Information
1. Mechanism(s) of Support
2. Funds Available
Section III. Eligibility Information
1. Eligible Applicants
A. Eligible Institutions
B. Eligible Individuals
2.Cost Sharing or Matching
3. Other - Special Eligibility Criteria
Section IV. Application and Submission Information
1. Address to Request Application Information
2. Content and Form of Application Submission
3. Submission Dates and Times
A. Receipt and Review and Anticipated Start Dates
1. Letter of Intent
B. Sending an Application
C. Application Processing
4. Intergovernmental Review
5. Funding Restrictions
6. Other Submission Requirements
Section V. Application Review Information
1. Criteria
2. Review and Selection Process
A. Additional Review Criteria
B. Additional Review Considerations
C. Sharing Research Data
D. Sharing Research Resources
3. Anticipated Announcement and Award Dates
Section VI. Award Administration Information
1. Award Notices
2. Administrative and National Policy Requirements
A. Cooperative Agreement Terms and Conditions of Award
1. Principal Investigator Rights and
Responsibilities
2. CDC Responsibilities
3. Collaborative Responsibilities
3. Reporting
Section VII. Agency Contact(s)
1. Scientific/Research Contact(s)
2. Peer Review Contact(s)
3. Financial/ Grants Management Contact(s)
4. General Questions Contact(s)
Section VIII. Other Information - Required Federal Citations
Part II - Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
The CDC and NCIPC are committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010" and to measuring program performance as stipulated by the Government Performance and Review Act (GPRA). This RFA addresses Healthy People 2010 priority area of injury and violence prevention and is in alignment with NCIPC’s performance goal to conduct a targeted program of research to reduce injury-related death and disability. For more information, see www.health.gov/healthypeople and www.whitehouse.gov/omb/mgmt-gpra/.
This RFA announces the availability of fiscal year (FY) 2006 cooperative agreement funds to establish Urban Partnership Academic Centers of Excellence (U-PACE). The Centers are expected to actively foster an environment conducive to reciprocally beneficial collaborations among health scientists, social scientists and a targeted high-risk community, with the common goal of reducing youth interpersonal violence, injury and death. The research and programmatic activities of the U-PACE are to contribute to the reduction of youth violence in the targeted high-risk community. One U-PACE is expected to serve a high-risk community in Philadelphia. The other is expected to serve a high-risk community in a city with a rate of youth homicide (for persons 15-24 years of age) that is at least twice the national average and that is not currently being served by CDC’s National Academic Centers of Excellence (ACE) Program on Youth Violence funded under PA05018. The following cities are currently participating in CDC’s National ACE Program: Baltimore, MD, Boston, MA, Chicago, IL, Kailua-Waimanalo, HI, New York, NY, Oakland, CA, Richmond, VA, and Riverside, CA.
Measurable outcomes of the program will be in alignment with one (or more) of the following performance goals for NCIPC:
1. Increase the capacity of injury prevention and control programs to address the prevention of injuries and violence.
2. Monitor and detect fatal and non-fatal injuries.
3. Conduct a targeted program of research to reduce injury-related death and disability.
Youth violence is defined as the intentional use of physical force or power, threatened or actual, exerted by or against children, adolescents or young adults, ages 10-24, which results in or has a high likelihood of resulting in injury, death, psychological harm, maldevelopment, or deprivation. It includes violence between individuals or groups who may or may not know each other. It frequently takes place outside the home, in the streets, or in institutional settings, such as schools, workplaces, and prisons. Hereafter, youth violence and youth interpersonal violence will be used synonymously.
Community is defined as individuals residing or working in a geographical area, such as a catchment area or a neighborhood. A high-risk community is a community that has multiple risk factors for youth violence including an already high prevalence of violent behavior, injury, and death relative to another community as indicated by law enforcement and/or hospital data. Risk factors also include a high incidence of crime, high concentration of low-income residents, limited economic opportunity, high-rates of substance abuse and drug selling, and low community participation and social capital.
Youth violence has declined in most regions of the Nation in the past decade, but rates of violent injury and death and violence perpetration among youth remain unacceptably high. For instance, approximately 715,002 youth ages 10 to 24 were injured from violent acts in 2004 (CDC, 2005). Homicide is the second leading cause of death among 15- to 24- year-olds and the fifth leading cause of death among 10- to 14-year-olds. Among individuals known to have committed homicide in 2000, approximately 48% were age 24 or younger (CDC, 2005). Violence disproportionately affects youth living in urban communities (Baum, 2005). In an urban community, such as Philadelphia, almost two thirds of the perpetrators and 40 percent of the victims of homicide are 24 years old or younger, and the homicide rate among Philadelphian youth is five times higher than the national average (Tierney & Loizillon, 1999; Tierney, McClanahan, & Hangley, 2001).
Although urban communities are often most affected by youth violence, they typically are not involved as partners in the prioritization, implementation, and evaluation of community-based interventions. The inclusion of community residents, representatives of community organizations, and youth has the advantages of increasing the likelihood that interventions will be sensitive to the cultural uniqueness of a community, that community-specific barriers can be identified and addressed early in the intervention process to yield greater immediate impact, and that broad community support can be generated to adopt and sustain intervention efforts (Green, Daniel, & Novick, 2001; Scrimshaw, White, & Koplan, 2001).
Youth violence interventions often are focused on secondary prevention, such as identifying, incarcerating, and/or rehabilitating known juvenile offenders to prevent them from committing violent acts again. Although secondary prevention is important, primary prevention is necessary to protect youth from ever becoming victims or perpetrators of violence. Many interventions are also limited by a focus on individual risk factors and by a neglect of protective factors. Research suggestions that prevention activities should attend to the accumulation of risk factors, as youth with multiple risk factors are more likely to become violent than youth exposed to only one risk factor (Herrenkohl et al., 2000), and that interventions should address both risk and protective factors (DHHS, 2001). It is important to pay attention to factors such as early aggressive behavior, social problem solving skill deficits, parental influences, and exposures to violence (e.g., media, witnessing violence in the home and community or associations with delinquent peers). These factors need to be addressed at the individual, peer/family, and community level. Attention to the role larger sociocultural, economic, and community factors play in the development and display of youth violence is also important because of the disproportionate impact of youth violence in some environments, such as urban communities.
To support a move toward primary prevention and the use of multifaceted approaches, proposed Centers are expected to draw from youth violence prevention programs that have documented efficacy [see the CDC’s Best Practices of Youth Violence Prevention: A Sourcebook for Community Action (2002); Surgeon General Report on Youth Violence (2001); Center for the Study and Prevention of Violence’s Blueprints on Violence (2005)] and to adapt research and programmatic activities to fit the targeted high-risk community s cultural framework and the risk and protective factors specific to the youth, families, schools, and high-risk community as a whole.
The goal of each U-PACE is to actively build reciprocally beneficial collaborations among health scientists, social scientists, and the targeted community and to reduce the incidence of youth violence, injury and death in the targeted high-risk community by achieving the following objectives:
Research funded under this announcement is expected to adhere to high scientific standards and to incorporate the following elements:
See Section VIII, Other Information
- Required Federal Citations, for policies related to this announcement.
Section II. Award
Information
1. Mechanism(s) of Support
This funding opportunity will
use the U49 (research cooperative agreement) award
mechanism.
This funding opportunity uses the just-in-time budget concepts. It also uses
the non-modular budget format described in the PHS 398 application instructions
(see http://grants.nih.gov/grants/funding/phs398/phs398.html).
A detailed categorical budget for the "Initial Budget Period" and the
"Entire Proposed Period of Support" is to be submitted with the
application.
The CDC
U49 is a cooperative agreement award mechanism. In the cooperative agreement
mechanism, the Principal Investigator retains the primary responsibility and
dominant role for planning, directing, and executing the proposed project, with
CDC staff being substantially involved as a partner with the Principal
Investigator, as described under the Section VI. 2. Administrative
Requirements, Cooperative Agreement Terms and Conditions of Award .
2. Funds Available
The participating CIO NCIPC, intends to commit approximately $1.7 million (includes direct and indirect costs) in FY 2006 to fund two awards in response to this RFA. The average award amount will be $851,400 for the first 12-month budget period, including both direct and indirect costs. An applicant may request a project period of up to five years. An applicant may request up to $851,400 for the first 12-month budget period. The approximate total project period funded amount is $4.25 million per Center. The anticipated start date for new awards is September 2006.
All estimated funding amounts are subject to availability of funds.
If you request a funding amount greater than the ceiling of the award range, your application will be considered non-responsive, and will not be entered into the review process. You will be notified that your application did not meet the submission requirements.
Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. Although the financial plans of NCIPC provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications. Additionally, the availability of funds are contingent upon evidence of satisfactory progress by the recipient (as documented in required reports), and the determination that continued funding is in the best interest of the Federal Government.
Facilities and administrative costs requested by consortium participants are not included in the direct cost limitation, see NOT-OD-05-004.
Section III. Eligibility Information
1. Eligible Applicants
1.A. Eligible Institutions
You may submit (an)
application(s) if your organization has any of the following characteristics:
A Bona Fide Agent is an agency/organization identified by the academic institution/center as eligible to submit an application under the academic institution/center in lieu of an academic institution/center application. If you are applying as a bona fide agent of an academic institution/center, you must provide a letter from the academic institution/center as documentation of your status. Place this documentation behind the first page of your application form.
Eligible applicants may enter into contracts, including consortia agreements, as necessary to meet the requirements of the RFA and to strengthen the overall application.
1.B. Eligible Individuals
Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for CDC programs.
In order for the application to be deemed responsive and entered into the review process, the following requirements for the principle investigator must be met:
2. Cost Sharing or Matching
Cost sharing, matching funds, or cost participation are
not required.
The most current Grants Policy Statement can be found at: http://grants.nih.gov/grants/policy/policy.htm.
3. Other-Special Eligibility Criteria
Special eligibility
criteria to be deemed responsive to this RFA include the following:
If your application is incomplete or non-responsive to the special requirements listed in this section, it will not be entered into the review process.
Note: Title 2 of the United States Code Section 1611 states that an organization described in Section 501(c)(4) of the Internal Revenue Code that engages in lobbying activities is not eligible to receive Federal funds constituting an award, grant, or loan.
Section IV. Application and Submission Information
1. Address to Request Application Information
The PHS 398 application instructions are available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. Applicants must use the currently approved version of the PHS 398. For further assistance contact GrantsInfo, Telephone (301) 710-0267, Email: GrantsInfo@nih.gov.
CDC Telecommunications for the hearing impaired: TTY 770-488-2783.
2.
Content and Form of Application Submission
Applications
must be prepared using the most current PHS 398 research grant application
instructions and forms. If the instructions in this announcement differ in any
way from the PHS 398 instructions, please follow the instructions in this
announcement. Applications must have a Dun & Bradstreet (D&B) Data
Universal Numbering System number as the universal identifier when applying for
Federal grants or cooperative agreements. The D&B number can be obtained by calling (866)
705-5711 or through the web site at http://www.dnb.com/us/.
The D&B number should be entered on line 11 of the face page of the PHS 398
form.
The title and number of this funding opportunity must be typed on line 2 of the
face page of the application form and the YES box must be checked.
The following instructions for writing the Description (abstract) and developing the research plan supersede those provided in the PHS 398 instructions. The Description included on page 2 of PHS 398 will be used to help determine the responsiveness of the application and to aid in the review process. Accordingly, the following elements should be included in the Description: (1) the overall mission of the Center, including specific goals and objectives; (2) the targeted high-risk community to be served by the Center’s research and programmatic efforts; (3) the identification and role of other collaborators and partners; and (4) a brief description of key elements (e.g., proposed core research project, including the essential features of the interventions, methods, and measures; the smaller research studies and programmatic activities; surveillance activities, and the dissemination plan). The language of the abstract must be simple and easy to understand for a broad audience.
Please follow the instructions below in developing your research plan. The research plan should consist of the following information:
I. Overall Description of the Proposed U-PACE (~ 8 pages): Applicants should provide an overall description of the proposed Center and develop a plan for evaluating the Center’s progress toward achieving its goals and objectives. Applicants should provide, at a minimum, the following:
II. Administrative and Infrastructure Core (~ 10 pages): To ensure that applicants have the administrative and infrastructure capacity to achieve the program goals and objectives, applicants should describe the following:
III. Research Core (~18 pages): Applicants should describe the U-PACE’s five-year research agenda, including a description of the core youth violence primary prevention research project(s), and smaller studies and programmatic activities, as described below. Clear definitions of procedures used to select proposed and future projects are required. To assure that applicants have the capacity to conduct the identified core youth violence prevention research and other research and programmatic activities, they should, at a minimum, describe: their ability to effectively collaborate with partners in the prioritization, planning, implementation, evaluation, and dissemination of research; and experience in successfully conducting, evaluating, and publishing youth interpersonal violence prevention research in the past five years, including community involvement in those activities.
The applicant should use the following template to describe each proposed research project.
i. Efficacy/effectiveness studies should address both risk and protective factors at two or more levels of influence (e.g., individual, family, peers, school/workplace, neighborhood, community). Such studies are expected to be rigorous and should include the collection of process measures (e.g., specific intervention components delivered, youth engaged in the various parts of the intervention) and outcome measures (i.e., violent behavior and injuries in the population of interest).
ii. Dissemination research studies should select measures and methods appropriate for the interventions, policies or programs chosen. The interventions, policies or programs chosen for dissemination research should be selected based on systematic reviews of the field or two or more well designed studies.
iii. Depending on the nature of the efficacy/effectiveness studies or the dissemination research studies conducted, individual- and community-level measures may be needed to examine impact. Cost data on programs and their implementation should be collected and utilized in cost-effectiveness analyses.
V. Communication and Dissemination Core (~ 6 pages): Applicants should outline a communication and dissemination plan to accomplish U-PACE goals and objectives. The outline should include how the U-PACE’s findings, methods, and tools will be disseminated and made available to different audiences, and how the U-PACE’s stakeholders (e.g., researchers, practitioners, community members, and policy makers) will be kept abreast of accomplishments. The outline should address how the U-PACE will develop products that reflect research progress and results; and describe how they will participate in coordinated activities with other urban areas to facilitate linkages and to promote national/state/local partnerships. Attention should be given to the role members of the targeted community will play in the development and dissemination of information. The outline should also describe the infrastructure of resources and personnel necessary to support communication and dissemination activities.
The application narrative should be no more than 50 pages (8.5 X 11 ), single-spaced, and printed on one side only, with one-inch margins on all sides and unreduced 12-point font. Appendices must be hard copy documents (i.e., no audiovisual materials or posters). The appendix should not be used to circumvent the page limitation. The appendix may include the following items: 1) letters of support and memorandum’s of understanding; 2) Up to 5 publications, manuscripts (accepted for publication), abstracts, patents, or other printed materials directly relevant to the application; 3) Other relevant supporting documentation.
To facilitate the preparation and review of the application, the application components should be organized according to the Table of Contents listed below. The list below supersedes the instructions contained in the PHS 398.
An applicant organization has the option of having specific salary and fringe benefit amounts for individuals omitted from the copies of the application that are made available to outside reviewing groups. To exercise this option, on the original and four copies of the application, the applicant must use asterisks to indicate those individuals for whom salaries and fringe benefits are not shown; however, the subtotals must still be shown. In addition, the applicant must submit an additional copy of page four of Form PHS-398, completed in full, with the asterisks replaced by the salaries and fringe benefits. This budget page will be reserved for internal staff use only.
3. Submission Dates and Times
All requested information
must be received in the CDC Procurement and Grants Office by 4:00 p.m. Eastern Time on or before the deadline date. If you submit your application by the United
States Postal Service or commercial delivery service, you must ensure that the
carrier will be able to guarantee delivery by the closing date and time. If
CDC receives your submission after closing due to: (1) carrier error, when the
carrier accepted the package with a guarantee for delivery by the closing date
and time, or (2) significant weather delays or natural disasters, you will be
given the opportunity to submit documentation of the carrier’s guarantee. If
the documentation verifies a carrier problem, CDC will consider the submission
as having been received by the deadline.
This announcement is the definitive guide on LOI and application content, submission address, and deadline. It supersedes information provided in the application instructions. If your application does not meet the deadline above, it will not be eligible for review, and will be discarded. You will be notified that you did not meet the submission requirements.
Otherwise, CDC will not notify you upon receipt of your
submission. If you have a question about the receipt of your LOI or
application, first contact your courier. If you still have a question, contact
the PGO-TIM staff at: 770-488-2700. Before calling, please wait two to three
days after the submission deadline. This will allow time for submissions to be
processed and logged.
3.A.
Receipt, Review and Anticipated Start Dates
Letter of Intent Receipt
Date: February 28, 2006
Application Receipt Date: March 30, 2006
Peer Review Date: May 2006
Council Review Date: June 2006
Earliest Anticipated Start Date: September 2006
3.A.1. Letter of Intent
Prospective applicants are asked to submit a letter of intent
that includes the following information:
Although a letter of intent is not required, is not binding, and does not enter into the review of the subsequent application, the information that it contains allows NCIPC staff to estimate the potential review workload and plan the review.
The letter of intent is to be sent by the date listed in Section IV.3.A
The letter of intent should be sent to:
NCIPC Extramural Resources Team
CDC, National Center for Injury Prevention and Control
Address for Express Mail or Delivery Service:
2945 Flowers Road
Yale Building,
Room 2054
Atlanta, GA 30341
Address for U.S. Postal Service Mail:
4770 Buford Hwy., NE,
Mailstop K-62
Atlanta, GA 30341
Telephone: 770-488-4037
Fax: 770-488-1662
Email: CIPERT@CDC.GOV
3.B.
Sending an Application
Applications
follow the PHS 398 application instructions for content and formatting of your
applications. If the instructions in this announcement differ in any way from
the PHS 398 instructions, follow the instructions in this announcement.
Applications
must be prepared using the research grant applications found in the PHS 398
instructions for preparing a research grant application. Submit a signed,
typewritten original of the application and all appendices, including the
checklist, and one signed photocopy in one package to:
Technical Information Management RFA-CE06-008
CDC
Procurements and Grants Office
2920
Brandywine Road
Atlanta, GA 30341
At the time of submission, four (4) additional copies of the application, including the appendix material, must be sent to:
NCIPC Extramural Resources Team
CDC, National Center for Injury Prevention and Control
Address for Express Mail or Delivery Service:
2945 Flowers Road
Yale Building,
Room 2054
Atlanta, GA 30341
Address for U.S. Postal Service Mail:
4770 Buford Hwy., NE,
Mailstop K-62
Atlanta, GA 30341
Fax: 770-488-1662
Email: CIPERT@CDC.GOV
Note: Applications must be sent to CDC in Atlanta, GA not NIH in Bethesda, MD.
3.C.
Application Processing
Applications must be received on or before the application receipt date(s) described
above (Section IV.3.A.). If an application is received after that date, it will be
returned to the applicant without review. Upon receipt, applications will be
evaluated for completeness by the PGO and for responsiveness by NCIPC and PGO.
Incomplete and non-responsive applications will not be reviewed.
4. Intergovernmental Review
Executive
Order 12372 does not apply to this program.
5. Funding
Restrictions
All CDC awards are subject to
the terms and conditions, cost principles, and other considerations described
in the PHS Grants
Policy Statement.
Restrictions, which must be taken into account while writing your budget, are as follows:
Awardees must agree to the Cooperative Agreement Terms and Conditions of Award in Section VI. Award Administration Information .
If you are requesting indirect costs in your budget, you must include a copy of your indirect cost rate agreement. If your indirect cost rate is a provisional rate, the agreement should be less than 12 months of age.
Your research plan should address activities to be conducted over the entire project period.
Plan for Sharing Research Data
The precise content of the data-sharing plan will vary, depending on the data being collected and how the investigator is planning to share the data. Applicants may wish to describe briefly the expected schedule for data sharing, the format of the final dataset, the documentation to be provided, whether or not any analytic tools also will be provided, whether or not a data-sharing agreement will be required and, if so, a brief description of such an agreement (including the criteria for deciding who can receive the data and whether or not any conditions will be placed on their use), and the mode of data sharing (e.g., under their own auspices by mailing a disk or posting data on their institutional or personal website, through a data archive or enclave). References to data sharing may also be appropriate in other sections of the application.
Proposals submitted to NCIPC for individual research projects of $500,000 or more in total (direct and indirect) costs per year require the applicant to include a data-sharing plan. As such, if any of the U-PACE’s proposed research projects exceed $500,000 per year in total costs, a data sharing plan for that proposed research project must be included in the application.
All applicants must include a plan for sharing research data in their application. The data sharing policy is available at http://www.cdc.gov/od/pgo/funding/ARs.htm under Additional Requirements 25 Release and Sharing of Data. All investigators responding to this funding opportunity should include a description of how final research data will be shared, or explain why data sharing is not possible.
The reasonableness of the data sharing plan or the rationale for not sharing research data will be assessed by the reviewers. However, reviewers will not factor the proposed data sharing plan into the determination of scientific merit or the priority score.
Sharing
Research Resources
Not applicable
Section V. Application Review Information
1. Criteria
The following will be
considered in making funding decisions:
2. Review and Selection Process
Applications that are
complete and responsive to the RFA will be evaluated for scientific and
technical merit by an appropriate peer review group convened by NCIPC in
accordance with the review criteria stated below.
As part of the initial merit review, all responsive applications will:
The goals of CDC-supported research are to advance the understanding of health promotion and prevention of disease, injury, and disability, and enhance preparedness. In the written comments, reviewers will be asked to evaluate the application in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals.
Significance: Is the Center addressing an important problem and reaching an important population? If the aims of the application are achieved, how will scientific knowledge or practice be advanced? What will be the effect of the Center’s studies and programmatic efforts on the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Approach: Are the conceptual or clinical framework, design, methods, and analyses adequately developed, well integrated, well reasoned, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics? Does the U-PACE’s approach reflect an emphasis on primary prevention of youth violence? Do proposed research and programmatic activities adequately address both risk and protective factors and multiple levels of influence on youth violence? Is the target high-risk community fully described and has the applicant provided a justification for the selection of the target high-risk community? Do the proposed activities adequately involve members of the target community in the prioritization, planning, implementation, and evaluation of youth violence prevention activities? Is the five-year evaluation plan sufficient to appropriately evaluate each component of the logic model and all core activities? Are the proposed research designs for the core project(s) and smaller studies scientifically rigorous and appropriate to answer the research questions? Do the smaller studies or programmatic activities compliment the core research project(s)? Are descriptions of sampling methods, sample size and power estimates, and measures of fidelity and program exposure, and outcome measures well described, concrete, specific, and appropriate for addressing research questions? Are the proposed surveillance efforts adequate to determine the impact of the proposed activities in the targeted community?
Innovation: Is the
project original and innovative? For example: Does the project challenge
existing paradigms or clinical practice; address an innovative hypothesis or
critical barrier to progress in the field? Does the project develop or employ
novel concepts, approaches, methodologies, tools, or technologies for this
area? Are plans for involving partners and members of the community in the
development, implementation, evaluation, and dissemination of youth violence
prevention activities innovative? Do the planned communication and
dissemination efforts employ novel approaches?
Investigators: Are
the investigators appropriately trained and well suited to carry out this work?
Is the work proposed appropriate to the experience level of the principal
investigator and other researchers? Does the investigative team bring
complementary and integrated expertise to the project (if applicable)? Do the investigators have adequate experience to conduct
process, outcome, and impact evaluations? Do the investigators have the
necessary training and experience to establish partnerships with
representatives of an urban community in order to achieve the proposed goals
and objectives? Do the principal investigator and the members of the research
team have a prior history of conducting, evaluating, and publishing violence
prevention research in the past five years? Does the principal investigator and
research team have prior experience working with the targeted community on
youth violence prevention activities? Do the investigators have experience
analyzing and disseminating youth violence research to a broad range of
audiences and through a variety of mechanisms?
Environment: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed studies benefit from unique features of the scientific environment, or subject populations, or employ useful collaborative arrangements? Is there evidence of institutional support? Is the infrastructure of personnel and resources required to develop U-PACE functions and processes and to accomplish stated goals and objectives adequately defined and described? Is there evidence that the applicant can maintain the infrastructure necessary to accomplish the proposed goals and objectives? Is an organizational chart provided that shows all the necessary positions to accomplish the activities proposed in the logic model and have core faculty and other staff been identified for key roles, including leadership, research, evaluation, dissemination, information management, and fiscal and program administration? Are members of the targeted community and other partners well integrated into U-PACE activities? Is there sufficient evidence of support for the five-year research plan by the academic institution and by members of the target community and other partners?
The primary review will be a peer review conducted by NCIPC Initial Review Group (IRG). Applications may be subjected to a preliminary evaluation (streamline review) by the IRG to determine if the application is of sufficient technical and scientific merit to warrant further review. NCIPC will withdraw from further consideration applications judged to be noncompetitive and promptly notify the principal investigator/program director and the official signing for the applicant organization. Those applications judged to be competitive will be further evaluated by the IRG. These applications will be reviewed for scientific merit using current NIH criteria (a scoring system of 100 - 500 points) to evaluate the methods and scientific quality of the application. The IRG may recommend the application for a site visit review that may involve a team of peer reviewers conducting an on-site visit, generating summary statements based upon the visit, and reporting the assessment to the IRG.
The secondary review will be conducted by the Science and Program Review Subcommittee (SPRS) of the Advisory Committee for Injury Prevention and Control (ACIPC). The ACIPC Federal agency experts will be invited to attend the secondary review and will receive modified briefing books (i.e., abstracts, strengths and weaknesses from summary statements, and project officer’s briefing materials). ACIPC Federal agency experts will be encouraged to participate in deliberations when applications address overlapping areas of research interest, so that unwarranted duplication in federally-funded research can be avoided and special subject area expertise can be shared. The NCIPC Division Associate Directors for Science (ADS) or their designees will attend the secondary review in a similar capacity as the ACIPC Federal agency experts to assure that research priorities of the announcement are understood and to provide background regarding current research activities. Only SPRS members will vote on funding recommendations, and their recommendations will be carried to the entire ACIPC for voting by the ACIPC members in closed session. If any further review is needed by the ACIPC, regarding the recommendations of the SPRS, the factors considered will be the same as those considered by the SPRS.
The ACIPC committee’s responsibility is to develop funding recommendations for the NCIPC Director based on the results of the primary review, the relevance and balance of proposed research relative to the NCIPC programs and priorities, and to assure that unwarranted duplication of federally-funded research does not occur. The secondary review committee has the latitude to recommend to the NCIPC Director, to reach over better ranked proposals in order to assure maximal impact and balance of proposed research. The factors to be considered will include:
All awards will be determined by the Director of the NCIPC based on priority scores assigned to applications by the primary review committee IRG, recommendations by the secondary review committee of the Science and Program Review Subcommittee of the ACIPC, consultation with NCIPC senior staff, and the availability of funds.
2.A. Additional Review
Criteria:
In addition to the above
criteria, the following items will continue to be considered in the
determination of scientific merit and the priority score:
Protection of Human Subjects from Research Risk: The involvement of human subjects and protections from research risk relating to their participation in the proposed research will be assessed (see the Research Plan, Section E on Human Subjects in the PHS Form 398). http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm. Additional CDC Requirements under AR-1 Human Subjects Requirements can be found on http://www.cdc.gov/od/pgo/funding/ARs.htm.
Inclusion of Women and Minorities in Research: Does the application adequately address the CDC Policy requirements regarding the inclusion of women, ethnic, and racial groups in the proposed research? This includes: (1) The proposed plan for the inclusion of both sexes and racial and ethnic minority populations for appropriate representation; (2) The proposed justification when representation is limited or absent; (3) A statement as to whether the design of the study is adequate to measure differences when warranted; and (4) A statement as to whether the plans for recruitment and outreach for study participants include the process of establishing partnerships with community(ies) and recognition of mutual benefits.
2.B. Additional Review Considerations
Budget: The reasonableness of the proposed
budget and the requested period of support in relation to the proposed
research. The priority score should not be affected by the evaluation of the
budget.
2.C. Sharing Research Data
Data Sharing Plan: The reasonableness of the data sharing plan or the rationale for not sharing research data will be assessed by the reviewers. However, reviewers will not factor the proposed data sharing plan into the determination of scientific merit or the priority score. The presence of a data sharing plan will be part of the terms and conditions of the award. The funding organization will be responsible for monitoring the data sharing policy.
Proposals submitted to NCIPC for individual research projects of $500,000 or more in total (direct and indirect) costs per year require the applicant to include a data-sharing plan. As such, if any of the U-PACE s proposed research projects exceed $500,000 per year in total costs, a data sharing plan for that proposed research project must be included in the application.
2.D.
Sharing Research Resources
Not applicable
3. Anticipated Announcement and Award Dates
Grantees will be notified in August or early September of
2006 by CDC’s Procurement and Grants Office (PGO) if their applications were
funded. It is anticipated that awards will be made in September 2006.
Section VI. Award
Administration Information
1. Award Notices
After the peer review of the
application is completed, the Principal Investigator will also receive a
written critique called a Summary Statement.
Those applicants under consideration for funding will be contacted by CDC for additional information.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization. The notice of award signed by the Grants Management Officer (GMO) is the authorizing document. This document will be mailed and/or emailed to the recipient fiscal officer identified in the application.
Selection
of the application for award is not an authorization to begin performance. Any
cost incurred before receipt of the NoA is at the recipient’s risk. These
costs may be reimbursed only to the extent considered allowable pre-award
costs. See also Section IV.5. Funding Restrictions.
2. Administrative and National
Policy Requirements
The Code of Federal
Regulations 45 CFR Part 74 and Part 92 have details about policy requirements.
For more information on the Code of Federal Regulations, see the National
Archives and Records Administration at the following Internet address: http://www.access.gpo.gov/nara/cfr/cfr-table-search.html.
The following additional requirements can be found in Section VIII. Other
Information of this document or on the CDC website at the following Internet
address: http://www.cdc.gov/od/pgo/funding/ARs.htm.
These will be incorporated into the NoA by reference.
2.A. Cooperative Agreement Terms and Conditions of Award
The following special terms of award are in addition to, and not in lieu of, otherwise applicable OMB administrative guidelines, HHS grant administration regulations at 45 CFR Parts 74 and 92 (Part 92 is applicable when State and local Governments are eligible to apply), and other HHS, PHS, and CDC grant administration policies.
The administrative and funding instrument used for this program will be the cooperative agreement, an assistance mechanism (rather than an acquisition mechanism), in which substantial CDC programmatic involvement with the awardee is anticipated during the performance of the activities. Under the cooperative agreement, the CDC purpose is to support and stimulate the recipients activities by involvement in and other otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the CDC as defined above.
2.A.1. Principal Investigator Rights and Responsibilities
The Principal Investigator will have the primary responsibility for:
Awardees will retain custody of and have primary rights to the data and software developed under these awards, subject to Government rights of access consistent with current HHS, PHS, and CDC policies
2.A.2. CDC Responsibilities
A CDC Project Scientist will have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below.
Additionally, an agency program official or CIO program director will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice.
2.A.3.
Collaborative Responsibilities
Not applicable
3. Reporting
You must provide CDC with an
original, plus two hard copies of the following reports:
1. Interim/Grant Progress Report, (use form PHS 2590, OMB Number 0925-0001, rev. 9/04 as posted on the CDC website) no less than 120 days before the beginning of the budget period. The progress report will serve as your non-competing continuation application.
2. Annual Progress Report, due 90 days after the end of the budget period. Annual outcome reports should summarize the results, including publications, and the impact resulting from the research. An outcome report format will be sent by NCIPC to the grantees.
3. Financial status report, no more than 90 days after the end of the budget period.
4. Final financial and performance reports, no more than 90 days after the end of the project period.
These reports must be forward by U.S. Postal Service or Express Delivery to the Grants Management Specialist listed in the Agency Contacts section of this announcement.
At the completion of the project, the grant recipient will submit a final outcome report and a brief summary of the research written in non-scientific [laymen s] terms. The summary should highlight the findings and their implications for injury prevention programs, policies, environmental changes, etc. The grant recipient will also include a description of the dissemination plan for research findings. This plan will include publications in peer-reviewed journals and ways in which research findings will be made available to stakeholders outside of academia (e.g., state injury prevention program staff, community groups, public health injury prevention practitioners, and others). CDC will place the summary report and each grant recipient s final report with the National Technical Information Service (NTIS) to further the agency’s efforts to make the information more available and accessible to the public.
Although the financial plans of the CIO(s) provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds, evidence of satisfactory progress by the recipient (as documented in required reports) and the determination that continued funding is in the best interest of the Federal government.
We
encourage your inquiries concerning this funding opportunity and welcome the
opportunity to answer questions from potential applicants. Inquiries may fall
into three areas: scientific/research, peer review, and financial or grants
management issues:
1. Scientific/Research Contacts:
Linda Anne Valle, Ph.D
National Center for
Injury Prevention and Control
Centers for Disease Control and Prevention (CDC)
4770 Buford Highway, NE, Mailstop K-60
Atlanta, GA 30341
Telephone: 770-488-4297
FAX: 770-488-1011
E-mail: LValle@cdc.gov
2. Peer Review Contacts:
Gwendolyn
Cattledge, Ph.D
Scientific Review
Administrator
National Center for Injury Prevention and Control
Centers for Disease
Control and Prevention (CDC)
4770 Buford Highway, NE, Mailstop K-02
Atlanta, GA 30341
Telephone:
770-488-4655
FAX: 770-488-4422
E-mail:
gxc8@cdc.gov
3. Financial or Grants Management Contacts:
Brenda Hayes, Grants Management Specialist
CDC Procurement and Grants Office
2920 Brandywine Road
Atlanta, GA 30341
Telephone: 770-488-2741
FAX: 770-488-2670
E-mail: BHayes@cdc.gov
4. General
Questions Contacts:
Technical
Information Management Section
CDC
Procurement and Grants Office
2920
Brandywine Road
Atlanta,
GA 30341
Telephone:
770-488-2700
Email:
PGOTIM@cdc.gov
5. Special Guidelines for Technical Assistance:
Conference Call: Technical assistance will be available for potential applicants during one conference call. The call for eligible applicants will be held on February 14, 2006 from 2:00 p.m. to 3:30 p.m. (Eastern Time). The conference can be accessed by calling 1-877-951-7375 and entering access code 603639. Participation in this conference call is not mandatory.
NCIPC Website: For additional help in preparing your grant application please see the frequently asked questions section on the NCIPC webpage at: http://www.cdc.gov/ncipc/res-opps/2004pas.htm
Section VIII. Other Information
Required Federal Citations
Human Subjects Protection:
Federal regulations (45CFR46) require that applications and
proposals involving human subjects must be evaluated with reference to the
risks to the subjects, the adequacy of protection against these risks, the
potential benefits of the research to the subjects and others, and the
importance of the knowledge gained or to be gained (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).
Additional CDC Requirements under AR-1 Human Subjects Requirements can be found
on http://www.cdc.gov/od/pgo/funding/ARs.htm.
Requirements for Inclusion of Women and Racial and
Ethnic Minorities in Research
It is the policy of the Centers for Disease Control and Prevention (CDC) and the Agency for Toxic Substances and Disease Registry (ATSDR) to ensure that individuals of both sexes and the various racial and ethnic groups will be included in CDC/ATSDR-supported research projects involving human subjects, whenever feasible and appropriate. Racial and ethnic groups are those defined in OMB Directive No. 15 and include American Indian or Alaska Native, Asian, Black or African American, Hispanic or Latino, Native Hawaiian or Other Pacific Islander. Applicants shall ensure that women, racial and ethnic minority populations are appropriately represented in applications for research involving human subjects. Where clear and compelling rationale exist that inclusion is inappropriate or not feasible, this situation must be explained as part of the application. This policy does not apply to research studies when the investigator cannot control the race, ethnicity, and/or sex of subjects. Further guidance to this policy is contained in the Federal Register, Vol. 60, No. 179, pages 47947-47951, and dated Friday, September 15, 1995.
Paperwork
Reduction Act Requirements
Under the Paperwork Reduction Act, projects that involve the
collection of information from 10 or more individuals and funded by a grant or
a cooperative agreement will be subject to review and approval by the Office of
Management and Budget (OMB).
Smoke-Free Workplace Requirements
CDC strongly encourages all recipients to provide a smoke-free
workplace and to promote abstinence from all tobacco products. Public Law
103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities
that receive Federal funds in which education, library, day care, health care,
or early childhood development services are provided to children.
Healthy People 2010
The Public Health Service (PHS) is committed to achieving the
health promotion and disease prevention objectives of "Healthy People
2010," a PHS-led national activity for setting priority areas. This PA is
related to one or more of the priority areas. Potential applicants may obtain a
copy of "Healthy People 2010" at http://www.health.gov/healthypeople.
Lobbying Restrictions
Applicants should be aware of restrictions on the use of HHS
funds for lobbying of Federal or State legislative bodies. Under the provisions
of 31 U.S.C. Section 1352, recipients (and their sub-tier contractors) are
prohibited from using appropriated Federal funds (other than profits from a
Federal contract) for lobbying congress or any Federal agency in connection
with the award of a particular contract, grant, cooperative agreement, or loan.
This includes grants/cooperative agreements that, in whole or in part, involve
conferences for which Federal funds cannot be used directly or indirectly to
encourage participants to lobby or to instruct participants on how to lobby.
In addition no part of CDC appropriated funds, shall be used, other than for normal and recognized executive-legislative relationships, for publicity or propaganda purposes, for the preparation, distribution, or use of any kit, pamphlet, booklet, publication, radio, television, or video presentation designed to support or defeat legislation pending before the Congress or any State or local legislature, except in presentation to the Congress or any State or local legislature itself. No part of the appropriated funds shall be used to pay the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence legislation or appropriations pending before the Congress or any State or local legislature.
Any activity designed to influence action in regard to a particular piece of pending legislation would be considered "lobbying." That is lobbying for or against pending legislation, as well as indirect or "grass roots" lobbying efforts by award recipients that are directed at inducing members of the public to contact their elected representatives at the Federal or State levels to urge support of, or opposition to, pending legislative proposals is prohibited. As a matter of policy, CDC extends the prohibitions to lobbying with respect to local legislation and local legislative bodies.
The provisions are not intended to prohibit all interaction with the legislative branch, or to prohibit educational efforts pertaining to public health. Clearly there are circumstances when it is advisable and permissible to provide information to the legislative branch in order to foster implementation of prevention strategies to promote public health. However, it would not be permissible to influence, directly or indirectly, a specific piece of pending legislation
It remains permissible to use CDC funds to engage in activity to enhance prevention; collect and analyze data; publish and disseminate results of research and surveillance data; implement prevention strategies; conduct community outreach services; provide leadership and training, and foster safe and healthful environments.
Recipients of CDC grants and cooperative agreements need to be careful to prevent CDC funds from being used to influence or promote pending legislation. With respect to conferences, public events, publications, and "grassroots" activities that relate to specific legislation, recipients of CDC funds should give close attention to isolating and separating the appropriate use of CDC funds from non-CDC funds. CDC also cautions recipients of CDC funds to be careful not to give the appearance that CDC funds are being used to carry out activities in a manner that is prohibited under Federal law.
Prohibition on Use of CDC Funds for Certain Gun
Control Activities
The Departments of Labor, Health and Human Services, and
Education, and Related Agencies Appropriations Act specifies that: "None
of the funds made available for injury prevention and control at the Centers
for Disease Control and Prevention may be used to advocate or promote gun
control."
Anti-Lobbying Act requirements prohibit lobbying Congress with appropriated Federal monies. Specifically, this Act prohibits the use of Federal funds for direct or indirect communications intended or designed to influence a member of Congress with regard to specific Federal legislation. This prohibition includes the funding and assistance of public grassroots campaigns intended or designed to influence members of Congress with regard to specific legislation or appropriation by Congress.
In addition to the restrictions in the Anti-Lobbying Act, CDC interprets the language in the CDC's Appropriations Act to mean that CDC's funds may not be spent on political action or other activities designed to affect the passage of specific Federal, State, or local legislation intended to restrict or control the purchase or use of firearms.
Small, Minority,
And Women-owned Business
It is a national policy to place a fair share of purchases
with small, minority and women-owned business firms. The Department of Health
and Human Services is strongly committed to the objective of this policy and
encourages all recipients of its grants and cooperative agreements to take
affirmative steps to ensure such fairness. In particular, recipients should:
1. Place small, minority, women-owned business firms on bidders mailing lists.
2. Solicit these firms whenever they are potential sources of supplies, equipment, construction, or services.
3. Where feasible, divide total requirements into smaller needs, and set delivery schedules that will encourage participation by these firms.
4. Use the assistance of the Minority Business Development Agency of the Department of Commerce, the Office of Small and Disadvantaged Business Utilization, DHHS, and similar state and local offices.
Research Integrity
The signature of the institution
official on the face page of the application submitted under this Program
Announcement is certifying compliance with the Department of Health and Human
Services (DHHS) regulations in Title 42 Part 93, Subparts A-E, entitled PUBLIC
HEALTH SERVICE POLICIES ON RESEARCH MISCONDUCT.
The regulation places requirements on institutions receiving or applying for funds under the PHS Act that are monitored by the DHHS Office of Research Integrity (http://ori.hhs.gov./policies/statutes.shtml).
For example:
Section 93.301 Institutional assurances.(a) General policy. An institution with PHS supported biomedical or behavioral research, research training or activities related to that research or research training must provide PHS with an assurance of compliance with this part, satisfactory to the Secretary. PHS funding components may authorize [[Page 28389]] funds for biomedical and behavioral research, research training, or activities related to that research or research training only to institutions that have approved assurances and required renewals on file with ORI. (b) Institutional Assurance. The responsible institutional official must assure on behalf of the institution that the institution-- (1) Has written policies and procedures in compliance with this part for inquiring into and investigating allegations of research misconduct; and (2) Complies with its own policies and procedures and the requirements of this part.
Compliance with
Executive Order 13279
Faith-based organizations are eligible to
receive federal financial assistance, and their applications are evaluated in
the same manner and using the same criteria as those for non-faith-based
organizations in accordance with Executive Order 13279, Equal Protection of the
Laws for Faith-Based and Community Organizations. All applicants should,
however, be aware of restrictions on the use of direct financial assistance
form the Department of Health and Human Services (DHHS) for inherently
religious activities. Under the provisions of Title 45, Parts 74, 87, 92, and
96, organizations that receive direct financial assistance from DHHS under any
DHHS program may not engage in inherently religious activities, such as
worship, religious instruction, or proselytization as a part of the programs or
services funded with direct financial assistance from DHHS. If an organization
engages in such activities, it must offer them separately, in time and
location, from the programs or services funded with direct DHHS assistance, and
participation must be voluntary for the beneficiaries of the programs or
services funded with such assistance. A religious organization that
participates in the DHHS funded programs or services will retain its
independence from Federal, State, and local governments, and may continue to
carry out its mission, including the definition, practice, and expression of
its religious beliefs, provided that it does not use direct financial
assistance from DHHS to support inherently religious activities such as those described
above. A faith-based organization may, however, use space in its facilities to
provide programs or services funded with financial assistance from DHHS without
removing religious art, icons, scriptures, or other religious symbols. In
addition, a religious organization that receives financial assistance from DHHS
retains its authority over its internal governance, and it may retain religious
terms in its organization’s name, select its board members on a religious
basis, and include religious references in its organization’s mission
statements and other governing documents in accordance with all program
requirements, statutes, and other applicable requirements governing the conduct
of DHHS funded activities. For further guidance on the use of DHHS direct
financial assistance see Title 45, Code of Federal Regulations, Part 87, Equal
Treatment for Faith-Based Organizations, and visit the internet site: http://www.whitehouse.gov/government/fbci/
Health Insurance Portability and Accountability Act
Requirements
Recipients of this grant award should note that pursuant to
the Standards for Privacy of Individually Identifiable Health Information
promulgated under the Health Insurance Portability and Accountability Act
(HIPAA) (45 CFR Parts 160 and 164) covered entities may disclose protected
health information to public health authorities authorized by law to collect or
receive such information for the purpose of preventing or controlling disease,
injury, or disability, including, but not limited to, the reporting of disease,
injury, vital events such as birth or death, and the conduct of public health
surveillance, public health investigations, and public health interventions.
The definition of a public health authority includes a person or entity acting
under a grant of authority from or contract with such public agency. CDC
considers this project a public health activity consistent with the Standards
for Privacy of Individually Identifiable Health Information and CDC will
provide successful recipients a specific grant of public health authority for
the purposes of this project.
Release and Sharing of Data
The Data Release Plan is the Grantee's assurance that the
dissemination of any and all data collected under the CDC data sharing
agreement will be released as follows:
April 16, 2003, http://www.cdc.gov/od/foia/policies/sharing.htm and in full compliance with the 1996 Health Insurance Portability and Accountability Act (HIPPA), (where applicable), The Office of Management and Budget Circular A110, (2000) revised 2003, www.whitehouse.gov/omb/query.html?col=omb&qt=Releasing+and+Sharing+of+Data and Freedom of Information Act (FOIA) www.4.law.cornell.edu/uscode/5/5/552/html.
Applications must include a copy of the applicant's Data Release Plan. Applicants should provide CDC with appropriate documentation on the reliability of the data. Applications submitted without the required Plan may be ineligible for award. Award will be made when reviewing officials have approved an acceptable Plan. The successful applicant and the Program Manager will determine the documentation format. CDC recommends data is released in the form closest to micro data and one that will preserve confidentiality.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
| ||||||
![]() |
Department of Health and Human Services (HHS) |
![]() |
||||
NIH... Turning Discovery Into Health® |